摘要
目的:分析某部队医院2001～2005年β-内酰胺酶抑制药复合制剂临床用药情况。方法:统计分析各品种DDDs和日均费用,以及比较各分类药品DDDs和用药金额。结果:注射剂金额占主导,头孢菌素类占多数,且每年有所上升;2005年含他唑巴坦用药金额遥遥领先,1151万元占总金额的61.87%;结论:我院BLI复合制剂使用基本合理,但仍存在用药过度集中的问题。
Objective： To analyze the clinical application of compound preparations of β-1actamase inhibitors in our hospital during the period of 2001 -2005. Method： An analysis of DDDS, daily cost, DDDS and a mount of money of each kind of compound preparation was made. Result： A mount of money was mainly spent on injection, drugs Cephalospo- rins were majority. Their using rate increased year by year. Containing Tazobactam preparation were mainly used in clinic in 2005, 1151millions yuan was about 61.87%. Conclusion： Compound preparations of β-lactamase inhibitors appliction were basicly rational in clinical application , but still have the question of using too gathered.
出处
《药物流行病学杂志》
CAS
2007年第4期233-235,共3页
Chinese Journal of Pharmacoepidemiology
